Plain-English translation of NCT03151993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested a new medication called Fortelyzin () designed to dissolve blood clots during acute ischemic stroke. Researchers compared it head-to-head with (Actilyse), the standard clot-dissolving treatment that has been used for many years. The goal was to see whether the new medication could work as effectively and safely as the existing treatment.
Current stroke treatment requires the standard medication to be given as a quick initial dose followed by a longer infusion over an hour. This trial aimed to test whether a simpler approach—giving the new treatment as a single quick injection—could work just as well, potentially making emergency stroke care faster and easier to deliver.
If you qualified, you would have been randomly assigned to receive either the new medication (Fortelyzin) as a single injection or the standard treatment () as an initial bolus followed by an infusion. Both treatments were given intravenously in the hospital during your acute stroke care. Researchers then monitored you for safety and effectiveness to compare how well each medication worked at restoring blood flow and recovering from the stroke.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Russia